Therapeutic effects of ML-236B in primary hypercholesterolemia.
ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, was administered to 11 patients with primary hypercholesterolemia. After 4--8 weeks of drug treatment at doses of 50--150 mg/day, serum cholesterol levels were reduced by 11--37% (27% on average) in cases of heterozygous familial hypercholesterolemia and combined hyperlipidemia. A marked reduction in tuberous xanthomas was noticed in a homozygous case of familial hypercholesterolemia, but here the drug was less effective in reducing the serum cholesterol level and a higher dose was required for treatment. Softening of Achilles tendon xantomas was observed in a case of combined hyperlipidemia.
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008148:Lovastatin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D009281:Naphthalenes; C012258:mevastatin; D002784:Cholesterol; D008148:Lovastatin